Certara Reinforces D360’s Position as Dominant Big Data Platform for the Biopharmaceutical Industry

February 17, 2015

D360 version 8.0 supports connections to broader and more diverse data sets, increases collaboration across silos, and delivers faster time to insight for scientific decision making

PRINCETON, NJ – Feb. 17, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that it will be launching version 8.0 of its D360 R&D “big data” platform for the biopharmaceutical industry at the 22nd International Molecular Medicine Tri-Conference to be held Feb. 15-20 at the Moscone North Convention Center in San Francisco.

Certara’s D360 R&D data platform solves big data challenges faced by scientists and IT staff throughout biopharmaceutical organizations by integrating and leveraging the large amount of diverse scientific data generated by sponsor companies and their outsourced partners to optimize crucial R&D decisions.

“D360 breaks down barriers between R&D siloes, giving executives access to the entire discovery, pre-clinical and clinical data collection when they need to make the crucially-important go/no-go decision on new drug candidates. By allowing development teams to leverage existing research fully, D360 has enabled our clients to optimize compound development to achieve specific parameters, improve safety profiles of promising candidates, guide future studies based on scientific and statistical data, and anticipate regulatory questions. In addition, D360 provides the C-suite with a flexible solution which can be easily scaled to fit new outsourcing business models,” said Gavin Nichols, Certara’s president of technology and head of its Software Business Unit.

“By providing an end-to-end solution, D360 reduces the ongoing costs and time required to manage heterogeneous data platforms for the organization’s IT team. D360 also empowers scientific users by increasing the speed with which they can access information and making it easier for them to collaborate with other scientists,” Nichols added.

D360 provides scientific data integration, access, analysis, and visualization capabilities for early discovery through to the preclinical and clinical phases of drug development. D360 solves both intra and inter-domain research challenges by integrating data from multiple source systems to provide standard data views and data mining capabilities. In addition, D360 brings context and understanding to the data, enabling scientists to gain deeper insight and make better scientific decisions.

D360 v8.0 builds on the platform’s base capabilities and includes:

  • Connections to broader and more diverse data sets
  • New tools for collaboration within an organization and across external partners
  • Improved performance and usability, providing faster time to insight

For more information about D360, please click here or stop by Booth #508 at the Molecular Medicine Tri-Conference.

D360 image

About Certara
Certara is the global biosimulation technology-enabled drug development and drug safety consulting company. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.

Certara Contact:
Teresa A. Bradford, 919-852-4644
Senior Director, Marketing
teresa.bradford@certara.com

Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com

Learn More LinkedIn Twitter Facebook Email